ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3029% below fair value
$13.63+0.16 (+1.19%)
Close on Nov 17, 2026Market cap $3.05BP/E 19.5Yield –
ADMA Biologics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
ADMA Biologics's profit margin for the twelve months ending Jun 30, 2026 was 33.0%. For fiscal 2025 it was 28.8%, against 46.4% the year before. The highest annual figure on record is 46.4% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 28.8% | −17.6 |
| FY2024 | Dec 31, 2024 | 46.4% | +57.3 |
| FY2023 | Dec 31, 2023 | -10.9% | +31.8 |
| FY2022 | Dec 31, 2022 | -42.8% | +45.7 |
| FY2021 | Dec 31, 2021 | -88.5% | +90.9 |
| FY2020 | Dec 31, 2020 | -179.4% | −14.9 |
| FY2019 | Dec 31, 2019 | -164.5% | +222.6 |
| FY2018 | Dec 31, 2018 | -387.1% | −194.8 |
| FY2017 | Dec 31, 2017 | -192.3% | −9.2 |
| FY2016 | Dec 31, 2016 | -183.1% | +67.3 |
| FY2015 | Dec 31, 2015 | -250.4% | +33.9 |
| FY2014 | Dec 31, 2014 | -284.2% | +222.0 |
| FY2013 | Dec 31, 2013 | -506.2% | +146.8 |
| FY2012 | Dec 31, 2012 | -653.0% | +122.7 |
| FY2011 | Dec 31, 2011 | -775.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 30.4% | +2.4 |
| Q1 FY2026 | Mar 31, 2026 | 39.6% | +16.2 |
| Q4 FY2025 | Dec 31, 2025 | 35.5% | −59.7 |
| Q3 FY2025 | Sep 30, 2025 | 27.1% | −2.8 |
| Q2 FY2025 | Jun 30, 2025 | 28.1% | −1.9 |
| Q1 FY2025 | Mar 31, 2025 | 23.4% | +1.7 |
| Q4 FY2024 | Dec 31, 2024 | 95.2% | +119.1 |
| Q3 FY2024 | Sep 30, 2024 | 30.0% | +26.2 |
| Q2 FY2024 | Jun 30, 2024 | 29.9% | +40.5 |
| Q1 FY2024 | Mar 31, 2024 | 21.7% | +33.7 |
| Q4 FY2023 | Dec 31, 2023 | -23.9% | +0.6 |
| Q3 FY2023 | Sep 30, 2023 | 3.8% | +40.1 |
| Q2 FY2023 | Jun 30, 2023 | -10.6% | +30.0 |
| Q1 FY2023 | Mar 31, 2023 | -11.9% | +74.0 |
| Q4 FY2022 | Dec 31, 2022 | -24.5% | +38.6 |
| Q3 FY2022 | Sep 30, 2022 | -36.3% | +49.4 |
| Q2 FY2022 | Jun 30, 2022 | -40.6% | +65.4 |
| Q1 FY2022 | Mar 31, 2022 | -85.9% | +28.6 |
| Q4 FY2021 | Dec 31, 2021 | -63.1% | +76.0 |
| Q3 FY2021 | Sep 30, 2021 | -85.7% | +79.0 |
| Q2 FY2021 | Jun 30, 2021 | -106.0% | +153.1 |
| Q1 FY2021 | Mar 31, 2021 | -114.5% | +74.2 |
| Q4 FY2020 | Dec 31, 2020 | -139.1% | −51.3 |
| Q3 FY2020 | Sep 30, 2020 | -164.6% | −6.3 |
| Q2 FY2020 | Jun 30, 2020 | -259.1% | −57.7 |
| Q1 FY2020 | Mar 31, 2020 | -188.7% | +181.7 |
| Q4 FY2019 | Dec 31, 2019 | -87.7% | +356.9 |
| Q3 FY2019 | Sep 30, 2019 | -158.4% | +199.4 |
| Q2 FY2019 | Jun 30, 2019 | -201.4% | +115.3 |
| Q1 FY2019 | Mar 31, 2019 | -370.3% | +70.6 |
| Q4 FY2018 | Dec 31, 2018 | -444.7% | −336.5 |
| Q3 FY2018 | Sep 30, 2018 | -357.8% | −36.3 |
| Q2 FY2018 | Jun 30, 2018 | -316.7% | −50.9 |
| Q1 FY2018 | Mar 31, 2018 | -440.9% | −192.3 |
| Q4 FY2017 | Dec 31, 2017 | -108.2% | +28.8 |
| Q3 FY2017 | Sep 30, 2017 | -321.5% | −174.0 |
| Q2 FY2017 | Jun 30, 2017 | -265.8% | – |
| Q1 FY2017 | Mar 31, 2017 | -248.7% | – |
| Q4 FY2016 | Dec 31, 2016 | -137.0% | – |
| Q3 FY2016 | Sep 30, 2016 | -147.4% | – |
See a number that looks wrong?